Tolero Pharmaceuticals Presents Positive Interim Phase 2 Clinical Trial Results Of Alvocidib For The Treatment Of Front Line AML At 2014 American Society of Clinical Oncology Annual Meeting

Published: Jun 05, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SALT LAKE CITY--(BUSINESS WIRE)--Tolero Pharmaceuticals, Inc., a late clinical-stage biopharmaceutical company developing treatments for oncology and blood disorders, reported positive interim results from an ongoing, randomized Phase 2 clinical trial of its lead drug candidate, alvocidib, in combination with cytarabine plus mitoxantrone for previously untreated acute myeloid leukemia (AML) patients. In this clinical trial, which was presented by Joshua Zeidner, M.D., from Johns Hopkins University, patients with newly diagnosed, poor and intermediate risk AML, experienced complete response (CR) rates of 70% versus 46% with the standard of care (p=0.003). These data were reported at the 2014 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

Help employers find you! Check out all the jobs and post your resume.

Back to news